US 2023/0405004 A1 · COMBINATION THERAPY OF DONEPEZIL AND TADALAFIL FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR COGNITIVE IMPAIRMENT

Abstract

The present invention relates to a combination therapy of donepezil and tadalafil for the prevention, treatment or improvement of Alzheimer's disease or cognitive impairment. The combined administration of donepezil and tadalafil according to the present invention has a superior effect on improving Alzheimer's disease or cognitive impairment as compared to single administration of donepezil, which is able to be effectively used as a therapeutic therapy or a complex agent for Alzheimer's disease or cognitive impairment.

Claims10

Dependent claims

A composition for preventing, treating or improving Alzheimer's disease or cognitive impairment comprising:

(i) donepezil or a pharmaceutically acceptable salt thereof;
and
(ii) tadalafil or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application

18/035,245Filed 5 Nov 2021

Priority

KR 10-2020-01466775 Nov 2020

Published

21 Dec 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 31/445
Non condensed pyridines; Hydrogenated derivatives thereof: non condensed piperidines, e.g. piperocaine
A23L 33/10
Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof: using additives
A61K 31/27
Esters, e.g. nitroglycerine, selenocyanates: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
A61K 31/506
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: not condensed and containing further heterocyclic rings

Combination therapy of donepezil and tadalafil for the treatment of alzheimer's disease or cognitive impairment

Life of this patent

Combination therapy of donepezil and tadalafil for the treatment of alzheimer's disease or cognitive impairment

Life of this patent

Abstract

Claims10